
10 months ago
Dr. Zibo Li awarded three new projects
Funded by AccuNovo Biotechnologies Inc. and the NIH: STTR: Theranostic NTSR1-targeting Agents for Complementary Management of PSMA-negative Prostate Cancer The UNC team will work with Accunovo Biotech, Inc. to evaluate the newly developed agents in NTSR1 positive PC3 animal models. Specifically, UNC will perform 64Cu radiolabeling of NTSR1 targeted compounds that are developed by Accunovo …